Compare Stocks: FTH, IDYA, GMTX, and GRAL

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$32.97 -4.5%	$27.57	$7.45 ▼ $37.90	$851.95M	-0.25	212,636 shs	140,910 shs
GMTX Gemini Therapeutics	$82.41 +1.8%	$76.03	$1.16 ▼ $14.10	$3.57B	-0.12	189,291 shs	320,944 shs
GRAL GRAIL	$79.59 -3.6%	$69.83	$30.82 ▼ $118.84	$3.56B	3.24	922,484 shs	396,276 shs
IDYA IDEAYA Biosciences	$41.58 -2.1%	$36.57	$23.23 ▼ $42.68	$3.65B	-0.1	1.07 million shs	724,639 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	-0.55%	+4.61%	+22.02%	+3,451,999,900.00%	+3,451,999,900.00%
GMTX Gemini Therapeutics	+1.42%	+1.11%	+9.20%	+18.82%	+34.12%
GRAL GRAIL	+7.78%	+16.43%	+21.67%	+15.57%	+150.73%
IDYA IDEAYA Biosciences	+6.09%	+12.00%	+20.00%	+45.08%	+71.91%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
FTH Sensei Biotherapeutics	$32.97 -4.5%	$27.57	$7.45 ▼ $37.90	$851.95M	-0.25	212,636 shs	140,910 shs
GMTX Gemini Therapeutics	$82.41 +1.8%	$76.03	$1.16 ▼ $14.10	$3.57B	-0.12	189,291 shs	320,944 shs
GRAL GRAIL	$79.59 -3.6%	$69.83	$30.82 ▼ $118.84	$3.56B	3.24	922,484 shs	396,276 shs
IDYA IDEAYA Biosciences	$41.58 -2.1%	$36.57	$23.23 ▼ $42.68	$3.65B	-0.1	1.07 million shs	724,639 shs

7 Stocks to Buy And Hold Forever

Click the link to see MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
FTH Sensei Biotherapeutics	-0.55%	+4.61%	+22.02%	+3,451,999,900.00%	+3,451,999,900.00%
GMTX Gemini Therapeutics	+1.42%	+1.11%	+9.20%	+18.82%	+34.12%
GRAL GRAIL	+7.78%	+16.43%	+21.67%	+15.57%	+150.73%
IDYA IDEAYA Biosciences	+6.09%	+12.00%	+20.00%	+45.08%	+71.91%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
FTH Sensei Biotherapeutics	2.85	Moderate Buy	$55.00	60.68% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
GRAL GRAIL	2.30	Hold	$67.78	-14.31% Downside
IDYA IDEAYA Biosciences	2.81	Moderate Buy	$50.13	18.89% Upside

Current Analyst Ratings Breakdown

Latest FTH, IDYA, GMTX, and GRAL Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/21/2026	FTH Sensei Biotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$56.00
8/11/2026	FTH Sensei Biotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$60.00
8/5/2026	IDYA IDEAYA Biosciences	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$58.00 ➝ $60.00
8/5/2026	IDYA IDEAYA Biosciences	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$63.00 ➝ $59.00
8/4/2026	FTH Sensei Biotherapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$55.00
7/31/2026	FTH Sensei Biotherapeutics	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$56.00
7/28/2026	FTH Sensei Biotherapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$60.00
7/20/2026	FTH Sensei Biotherapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$51.00
7/17/2026	GRAL GRAIL	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	IDYA IDEAYA Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/16/2026	FTH Sensei Biotherapeutics	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$55.00

(Data available from 8/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	$6.69 per share	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
GRAL GRAIL	$147.17M	24.01	N/A	N/A	$56.93 per share	1.39
IDYA IDEAYA Biosciences	$218.71M	16.94	N/A	N/A	$13.65 per share	3.09

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
FTH Sensei Biotherapeutics	-$21.08M	-$141.65	N/A	N/A	N/A	N/A	-1,012.17%	-175.69%	N/A
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
GRAL GRAIL	-$408.35M	-$9.75	N/A	N/A	N/A	-236.95%	-15.88%	-14.02%	11/11/2026 (Estimated)
IDYA IDEAYA Biosciences	-$113.70M	-$1.94	N/A	N/A	N/A	-75.93%	-16.73%	-15.34%	11/3/2026 (Estimated)

Latest FTH, IDYA, GMTX, and GRAL Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	GRAL GRAIL	-$2.66	-$2.56	+$0.10	-$2.56	$42.39 million	$44.69 million
8/4/2026	Q2 2026	FTH Sensei Biotherapeutics	-$5.0450	-$2.84	+$2.2050	-$0.62	N/A	N/A
8/4/2026	Q2 2026	IDYA IDEAYA Biosciences	-$1.06	-$1.22	-$0.16	-$1.22	$8.02 million	$8.86 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
FTH Sensei Biotherapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
GRAL GRAIL	N/A	N/A	N/A	N/A	N/A
IDYA IDEAYA Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
FTH Sensei Biotherapeutics	N/A	19.69	19.69
GMTX Gemini Therapeutics	N/A	71.49	71.49
GRAL GRAIL	N/A	10.95	10.95
IDYA IDEAYA Biosciences	N/A	10.45	10.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
FTH Sensei Biotherapeutics	10.50%
GMTX Gemini Therapeutics	75.42%
GRAL GRAIL	N/A
IDYA IDEAYA Biosciences	98.29%

Insider Ownership

Company	Insider Ownership
FTH Sensei Biotherapeutics	7.00%
GMTX Gemini Therapeutics	12.90%
GRAL GRAIL	1.83%
IDYA IDEAYA Biosciences	4.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
FTH Sensei Biotherapeutics	40	25.84 million	24.03 million	Not Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
GRAL GRAIL	1,360	44.67 million	43.85 million	Optionable
IDYA IDEAYA Biosciences	80	87.86 million	83.73 million	Optionable

FTH, IDYA, GMTX, and GRAL Headlines

Recent News About These Companies

Odyssean LLC Buys 87,308 Shares of IDEAYA Biosciences, Inc. $IDYA

August 26 at 6:32 AM | marketbeat.com

Jupiter Topco LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

August 26 at 6:31 AM | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) Hits New 12-Month High - Here's Why

August 25 at 10:59 AM | marketbeat.com

Ideaya Biosciences: Darovasertib De-Risks A Self-Reinforcing Oncology Platform

August 25 at 10:00 AM | seekingalpha.com

Mitsubishi UFJ Asset Management Co. Ltd. Purchases Shares of 59,780 IDEAYA Biosciences, Inc. $IDYA

August 22, 2026 | marketbeat.com

Great Lakes Advisors LLC Makes New Investment in IDEAYA Biosciences, Inc. $IDYA

August 21, 2026 | marketbeat.com

Ideaya Biosciences, Genentech Partner for Pancreatic Cancer Trial

August 19, 2026 | finance.yahoo.com

IDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

August 19, 2026 | finanznachrichten.de

IDEAYA Biosciences Announces Clinical Collaboration with Genentech in MTAP-Deleted KRAS G12D-Mutant Pancreatic Cancer

August 19, 2026 | prnewswire.com

Bank of America Corp DE Has $31.39 Million Stake in IDEAYA Biosciences, Inc. $IDYA

August 16, 2026 | marketbeat.com

Walleye Capital LLC Buys Shares of 386,183 IDEAYA Biosciences, Inc. $IDYA

August 15, 2026 | marketbeat.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Given Average Recommendation of "Moderate Buy" by Brokerages

August 15, 2026 | americanbankingnews.com

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives Average Rating of "Moderate Buy" from Brokerages

August 15, 2026 | marketbeat.com

IDEAYA Biosciences (NASDAQ:IDYA) Rating Lowered to "Sell" at Wall Street Zen

August 15, 2026 | marketbeat.com

LifeSci Capital Sticks to Its Buy Rating for IDEAYA Biosciences (IDYA)

August 12, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: Icon (ICLR) and IDEAYA Biosciences (IDYA)

August 8, 2026 | theglobeandmail.com

Analysts Offer Insights on Healthcare Companies: IDEAYA Biosciences (IDYA) and TransMedics Group (TMDX)

August 6, 2026 | theglobeandmail.com

The Bull Case For IDEAYA Biosciences (IDYA) Could Change Following Wider Loss And New Roche Partnership

August 6, 2026 | finance.yahoo.com

IDEAYA Biosciences (NASDAQ:IDYA) Given New $59.00 Price Target at Truist Financial

August 5, 2026 | marketbeat.com

IDEAYA Biosciences Q2 Loss Widens From Q1, Revenue Rises

August 4, 2026 | finance.yahoo.com

IDEAYA Biosciences (NASDAQ:IDYA) Releases Quarterly Earnings Results, Misses Estimates By $0.16 EPS

August 4, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, IDYA, GMTX, and GRAL Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

$32.97 -1.55 (-4.49%)

As of 04:00 PM Eastern

Sensei Biotherapeutics, Inc., an immuno-oncology company, engages in the discovery and development of therapeutics for cancer patients. The company's Tumor Microenvironment Activated Biologics platform is designed to generate highly selective therapeutics that disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. It also offers SNS-101, an active monoclonal antibody that is in clinical Phase 1/2 targeting the immune checkpoint VISTA for the treatment of solid tumors. The company's pipeline includes SNS-103 and SNS-102, an active monoclonal antibody, which are in early development stages for the treatment of solid tumors, as well as SNS-201 is a bispecific antibody targeting CD28. It has a collaboration with The University of Washington to conduct preclinical studies for its SNS-101 program. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.

Gemini Therapeutics NASDAQ:GMTX

$82.41 +1.47 (+1.82%)

As of 08/25/2026

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

GRAIL NASDAQ:GRAL

$79.59 -2.95 (-3.57%)

As of 04:00 PM Eastern

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

IDEAYA Biosciences NASDAQ:IDYA

$41.58 -0.90 (-2.12%)

As of 04:00 PM Eastern

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, IDYA, GMTX, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, IDYA, GMTX, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, IDYA, GMTX, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, IDYA, GMTX, and GRAL Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Gemini Therapeutics NASDAQ:GMTX

GRAIL NASDAQ:GRAL

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest FTH, IDYA, GMTX, and GRAL Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest FTH, IDYA, GMTX, and GRAL Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

FTH, IDYA, GMTX, and GRAL Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

FTH, IDYA, GMTX, and GRAL Company Descriptions

Sensei Biotherapeutics NASDAQ:FTH

Gemini Therapeutics NASDAQ:GMTX

GRAIL NASDAQ:GRAL

IDEAYA Biosciences NASDAQ:IDYA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools